Eir Ventures welcomes Gökçe Günaydın as Investment Associate. Gökçe is joining from the pharmaceutical industry where she held global positions in Medical Affairs. She worked at the Karolinska Institute for 10 years, where she obtained her PhD. In 2021, she won the prestigious SSE MBA Carl Silfvén Scholarship allowing her to pursue her Executive MBA at Stockholm School of Economics. She is also the recipient of prestigious awards in the field of medical innovation.
“It is delightful that Synklino can extend its efforts to help transplant patients. We are also glad we at Eir Ventures have enabled the progress from academic project to a financeable promising company by our participation as seed investors” says Dr Magnus Persson, Founding Partner at Eir Ventures and Director of the Board at Synklino.
Congratulations to our portfolio company IO Biotech on the successful IPO on NASDAQ. Great achievement for this pioneering company, and a milestone in the development of new pioneering treatments for Cancer patients based on the company’s T-win technology.
BOSTON, Nov. 02, 2021 (GLOBE NEWSWIRE) — Galecto, Inc. (NASDAQ: GLTO), a publicly listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that it has entered into a clinical trial supply agreement with Roche to explore the combination of GB1211, Galecto’s oral galectin-3 inhibitor, with Roche’s PD-L1 checkpoint inhibitor atezolizumab (Tecentriq®) in Galecto’s planned Phase 2a trial in non-small-cell lung cancer (NSCLC).
Magnus Persson and Alexander Mata join the board of directors, with Magnus Persson as chairman.
one-carbon Therapeutics is a Swedish company specialized in targeting proteins involved in one-carbon metabolism and DNA damage and repair (DDR) as a way of inducing cancer cell death. The company is developing first-in-class inhibitors targeting MTHFD2, an oncofetal protein expressed during embryogenesis, silenced in adult cells, and then re-expressed in cancer. The lead program targets a range of cancer indications including leukemias and solid tumors with significant unmet medical needs and market potential.